Effect of a polynucleotide interferon inducer of fungal origin on experimental rhinovirus infection in humans.
A double-stranded RNA of fungal origin (BRL 5907) was given intranasally to volunteers. Apart from mild local irritancy of the higher dosage, the compound was well tolerated. A double-blind placebo-controlled trial of a three-day course (5 mg per day) of BRL 5907 against challenge with rhinovirus type 4 showed that treatment was associated with a delay in onset of symptoms and a reduction in shedding of virus, but the differences were not statistically significant. Low titers of interferon were found in nasal washings.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D005658:Fungi; D006801:Humans; D007108:Immune Tolerance; D007369:Interferon Inducers / Q000627:therapeutic use*; D007372:Interferons / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011070:Poly I-C; D012229:Rhinovirus; D014777:Virus Diseases / Q000628:therapy*
D007369:Interferon Inducers; D010919:Placebos; D007372:Interferons; D011070:Poly I-C